Peptest in patients with suspected gastro-oesophageal reflux disease
Research type
Research Study
Full title
Pilot study to investigate the use of Peptest for patients referred from primary care with suspected gastro-oesophageal reflux disease.
IRAS ID
167919
Contact name
Jeremy Huddy
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
0 years, 5 months, 1 days
Research summary
Peptest is a device to measure pepsin in saliva samples. Pepsin is an enzyme whose precursor pepsinogen is released by the chief cells in the stomach that degrades food proteins into peptides. Its presence in the gastrointestinal tract proximal to the stomach suggests GORD and hence recent studies have investigated pepsin as a diagnostic biomarker for gastro-oesophageal reflux disease. This study aims to further evaluate the role of Peptest in the diagnosis of reflux disease. The Peptest assay will be performed on patients presenting at a large North-West London teaching hospital for diagnostic upper gastro-intestinal endoscopy and compare the results with endoscopy findings. Current NICE guidelines are that symptomatic patients over 55 years should have an endoscopy. Therefore, this study will investigate the ability of Peptest to triage patients for upper GI endoscopy in the 18-55 year age group. This will generate further evidence of how this test can risk stratify patients for gastro-oesophageal reflux disease and the impact to clinical pathways.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
14/NE/1235
Date of REC Opinion
10 Dec 2014
REC opinion
Further Information Favourable Opinion